InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,498.31
(
-0.43%
)
US TECH 100
18,764.00
(
-0.42%
)
Dow Jones
40,515.71
(
-0.80%
)
Brent Oil
80.39
(
-1.38%
)
Bitcoin
64,062.27
(
-0.83%
)
Post# of 38376
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

JokersWild12

Send PM Follow Ignore
Followers 10
Posts 529
Boards Moderated 0
Alias Born 12/15/2011

JokersWild12

Re: JokersWild12 post# 38051

Thursday, 03/23/2017 5:47:33 PM

Thursday, March 23, 2017 5:47:33 PM

Post# of 38376
From the PR today at RGBP they are closing in on preclinical drug development, which would determine dosage safety for clinicals. 2 months as it looks to get through the LO. Want to hear where this is at with ENTB and what the timing going forward is. The new veterinarians will drive this.

Target validation (TV) ? assay development ? high-throughput screening ? hit to lead (H2L) ? lead optimization (LO) ? preclinical drug development ? clinical drug development.

These companies are all radically undervalued. Again noted in the PR that more than one large pharma company has shown interest already in RGBP. RGBP working with ChemDiv is positive to larger interest. Interest will only increase with continued positive results. $$$$.

ALL IMO. GL.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up